Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Jun 2026: Trial registered, NCT07650240
  2. 4 Aug 2026: Trial started, NCT07650240

The trials

NCT07650240: Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

State
Under way
Phase
Phase 2
People
202 planned
Started
4 Aug 2026
Primary completion
30 Dec 2030
Arms
Arm A1 (177Lu-PSMA-617, iADT), Arm B1 (177Lu-PSMA-617, iADT, iAA, P)
Results
None posted
  1. 16 Jun 2026: Trial registered
  2. 4 Aug 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.